Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;5(3):201-5.
doi: 10.1007/s13555-015-0082-5. Epub 2015 Aug 25.

5-Fluorouracil "Chemowraps" in the Treatment of Multiple Actinic Keratoses: A Norwich Experience

Peter K C Goon  1 , Rachel Clegg  2 , Adrian S W Yong  2   3 , Ava S W Lee  2 , Kevin Y C Lee  2 , Nick J Levell  2 , Eunice K H Tan  2 , Syed N Shah  2
Affiliations

5-Fluorouracil "Chemowraps" in the Treatment of Multiple Actinic Keratoses: A Norwich Experience

Peter K C Goon et al. Dermatol Ther (Heidelb). 2015 Sep.

Abstract

Introduction: Topical 5-fluorouracil (5-FU) has been used to treat actinic keratosis for decades. It has been an important and effective treatment which the patient can self-administer, but is limited by the surface area of skin to be treated (according to the manufacturer's guidelines) of 500 cm(2). Other topical treatments can be painful, or require hospital/health care professional input. The use of 5-FU under occlusion (chemowraps) for large areas of sun-damaged skin on the arms or legs has been described and is a potentially useful treatment option. We describe our experiences with this technique in the Norfolk and Norwich University Hospital Dermatology Department (Norwich, UK).

Methods: Five patients were recruited into this pilot study. Topical 5-FU was applied to sun-damaged limbs under occlusion, and reviewed weekly for response, and local or systemic side effects. Treatment duration was 12-14 weeks. Clinical photography was undertaken prior to, during, and after treatment to document response.

Results: We show that there was substantial clinical improvement in the treated skin in our patients. Experienced dermatologists reviewed all the patients, and documented the changes photographically, and by counting lesions. All patients were satisfied with their treatment regimen, and also with the end result; although two did not complete the treatment regimen due to complications not directly attributable to the treatment.

Conclusion: Topical 5-FU under occlusion (chemowraps) may be a valid treatment option for large areas of sun-damaged skin with field cancerization changes, due to low systemic and local toxicity, and acceptability to patients.

Keywords: Chemowraps; Field cancerization; Sun-damaged skin; Topical 5-fluorouracil.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Photos of two representative patients who completed chemowrap treatment. White arrows point to actinic keratoses or Bowenoid lesions which have evidently improved after treatment, by resolving completely, or diminishing in size and thickness
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015. doi:10.1001/jamadermatol.2015.0502. - PubMed
    1. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26(8):728–732. doi: 10.1046/j.1524-4725.2000.99197.x. - DOI - PubMed
    1. Mann M, Berk DR, Petersen J. Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol. 2008;7(7):685–688. - PubMed
    1. Tallon B, Turnbull N. 5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma. Australas J Dermatol. 2013;54(4):313–316. doi: 10.1111/ajd.12055. - DOI - PubMed
    1. Lee A, Ezzeldin H, Fourie J, Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol. 2004;2(8):527–532. - PubMed

LinkOut - more resources